Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Three components enable 3D kidney tissue from mouse embryonic stem cells

Feb. 8, 2022

Targeting NQO1 shows protective effects in models of diabetic nephropathy

Feb. 8, 2022

Anakuria's AT-20494 to be studied for ADPKD and other indications

Feb. 3, 2022

Vertex Pharmaceuticals identifies new APOL1 inhibitors

Jan. 5, 2022

Nephrology

Jan. 1, 2022

Novel XO inhibitors show efficacy in acute hyperuricemia rat model

Dec. 21, 2021

Chinook Therapeutics identifies LDHA inhibitors

Dec. 15, 2021

Chinook Therapeutics divulges LDHA inhibitors

Dec. 13, 2021

Lennham discloses deuterated testosterone compound

Nov. 11, 2021

UBE-1099: a novel Keap1-Nrf2 PPI inhibitor for kidney disease

Nov. 11, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...